rare-diseases-congress-2019-posters-abstracts

2 / 11

Notes:
Page 40
conferenceseries.com
Volume 04 Journal of Clinical Infectious Diseases & Practice
ISSN: 2476-213X Rare Diseases Congress 2019
June 17-18, 2019
June 17-18, 2019 | Berlin, Germany
9th World Congress on
Rare Diseases and Orphan Drugs
Non-dystrophic myotonic disorders: Patients’ insights on treatment access
Carina Schulmann Schey1, Foerster D2, Whiting A3, Kole A3, von Gallwitz P3 and Meier Y2
1University of Groningen, The Netherlands
2Lupin Atlantis Holdings, Switzerland
3admedicum® Business for Patients GmbH & Co KG, Germany
Background: Non-dystrophic myotonic (NDM) disorders are a heterogenous group of rare, genetic skeletal muscle
chloride and sodium channelopathies with altered membrane excitability resulting in prolonged muscle contraction
and delayed relaxation. Patients experience stiffness, pain, weakness, impaired mobility, fatigue, disability, falls,
problems with speech, chewing and swallowing. Patients with NDM experience unpredictable frequency and severity
of myotonic episodes, associated with life-long symptoms and negative impact on physical functioning and quality of
life. Treatment has included unlicensed products such as mexiletine. This study sought to evaluate the awareness and
access to mexiletine across Europe, and subsequent harm caused by limited treatment access. Following the study,
mexiletine gained European marketing authorisation.
Method: A two-stage study ascertaining the level of access to mexiletine and benefits for those treated with
mexiletine was developed and conducted in required languages. Healthcare experts and patient representatives were
interviewed, followed by an online survey for patients and caregivers, in 13 countries.
Results: Online questionnaires were completed by 37 NDM patients, of whom 41% were currently taking mexiletine.
Of those not taking mexiletine, 67% had never heard of mexiletine and 25% reported it not being available in their
country. Treatment was required by 67% of patients to allow muscle warming before physical exertion and 50% to
improve emotional well-being, and mexiletine drastically reduced frequency of falling in 44% of patients. Anxiety
about future access to mexiletine affected 87% of patients. Disruption in mexiletine treatment harmed 85% of
patients.
Conclusion: Mexiletine-treated patients experienced substantial benefits, while denied access resulted in substantial
harm.
Biography
Carina Schulmann Schey is pursuing her PhD in the economics of orphan drugs and assessing alternative ways to adjudicate their value-add in the management
of rare diseases. With a background as a Clinical Pharmacist with a special interest in rare diseases, she has published several peer-reviewed articles and
abstracts in rare diseases. She sits on the expert judges’ panel for the MassChallenge and on the scientific advisory panels for several charities, and as a Non-
Executive Director for healthcare organizations.
Carina Schulmann Schey et al., J Clin Infect Dis Pract 2019, Volume 04